Share Buyback

About this update from Ekf Diagnostics Holdings Plc

    EKF Diagnostics Holdings plc ("EKF" or the "Company")   Share Buyback   EKF Diagnostics Holdings plc  (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 400,000 of its ordinary shares of 1p each in the capital of the Company (" Ordinary Shares ") at a weighted average price of 24.5 pence per share. The purchased shares will be cancelled. Harwood Capital Management has not sold any ordinary shares to the Company as part of yesterday's purchases.   Aggregated information   Date of purchase 9 April 2026 Number of Ordinary Shares purchased 400,000 Highest price paid per Ordinary Share 24.5p Lowest price paid per Ordinary Share 24.5p Volume weighted average price paid 24.5p     Transaction details   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:   Number of Ordinary Shares purchased Transaction price (GBp) Time of transaction Trading venue 400,000 24.5p 13:53:10 AIMX   Total voting rights   Following the purchase and after the cancellation of the shares becomes effective, the Company's total issued share capital will consist of 430,503,112 Ordinary Shares. There are no shares held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 430,503,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.       This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).      The person responsible for arranging the release of this Announcement on behalf of the Company is Julian Baines, Executive Chair.     EKF Diagnostics Holdings plc www.ekfdiagnostics.com Julian Baines, Executive Chair  via Walbrook PR Gavin Jones, Chief Executive Officer   Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000 Phil Davies / Patrick Weaver Walbrook PR Limited Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654       About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )   EKF is an AIM-listed global diagnostics business focussed on:   ● Point-of-Care  analysers in the key areas of Hematology and Diabetes  ● Life Sciences  services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.   EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.    

View stock analysis, news, and events for Ekf Diagnostics Holdings Plc